Macrotroponin I: Lower Mortality Risk 09/09/26
Welcome to Cardiology Today â Recorded September 09, 2026. This episode summarizes 5 key cardiology studies on topics like Dilated cardiomyopathy and high-risk genotypes. Key takeaway: Macrotroponin I: Lower Mortality Risk.
Article Links:
Article 1: Tozorakimab to Prevent COPD Exacerbations. (The New England journal of medicine)
Article 2: Impaired Glycolysis Leads to Defective Efferocytosis and Impaired Plaque Resolution in Tet2 Clonal Hematopoiesis. (Circulation)
Article 3: Macrotroponin Complexes and Risk of Cardiovascular Events. (Circulation)
Article 4: Arrhythmic Risk Stratification According to LGE Corridors and Genetics in Nonischemic Dilated Cardiomyopathy. (Circulation)
Article 5: An Updated Evidence Assessment of the Genetic Causes of Dilated Cardiomyopathy. (Circulation)
Full episode page: https://podcast.explainheart.com/podcast/macrotroponin-i-lower-mortality-risk-09-09-26/
đ Featured Articles
Article 1: Tozorakimab to Prevent COPD Exacerbations.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/42708515
Summary: Tozorakimab is a monoclonal antibody that inhibits interleukin-33 activity, a key mechanism implicated in the pathogenesis of chronic obstructive pulmonary disease. This therapeutic approach targets the dysregulated signaling in patients who continue to experience exacerbations despite standard-of-care inhaled maintenance therapy. The OBERON and TITANIA phase three trials investigated tozorakimab for preventing exacerbations in adults with chronic obstructive pulmonary disease who were current or former smokers and had a history of exacerbations. The clinical focus is on providing a new preventative option for this high-risk patient population.
Article 2: Impaired Glycolysis Leads to Defective Efferocytosis and Impaired Plaque Resolution in Tet2 Clonal Hematopoiesis.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/42708224
Summary: The study found that TET2 (tet methylcytosine dioxygenase two) clonal hematopoiesis impairs glycolysis in macrophages. This impaired glycolysis leads to defective efferocytosis, consequently resulting in impaired plaque resolution within atherosclerotic plaques. The data showed that TET2 clonal hematopoiesis promotes atherosclerosis progression. These mechanisms were observed to impair plaque remodeling and regression even under conditions of low-density lipoprotein lowering.
Article 3: Macrotroponin Complexes and Risk of Cardiovascular Events.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/42708217
Summary: The study found that macrotroponin complexes were present in a general population cohort of 19499 participants, with macrotroponin I found in 0.8 percent and macrotroponin T in 0.2 percent. Results showed that macrotroponin I was associated with a lower risk of all-cause mortality, with a hazard ratio of 0.61 and a 95 percent confidence interval of 0.46 to 0.80. This association for macrotroponin I also extended to cardiovascular mortality, showing a hazard ratio of 0.52 with a 95 percent confidence interval of 0.30 to 0.90, even after adjusting for cardiac troponin levels and confounders. No significant association was observed between macrotroponin T and clinical outcomes.
Article 4: Arrhythmic Risk Stratification According to LGE Corridors and Genetics in Nonischemic Dilated Cardiomyopathy.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/42708210
Summary: The study found that late gadolinium enhancement (L. G. E.) corridors, assessed through cardiac magnetic resonance imaging, were an independent predictor of major ventricular arrhythmic events in nonischemic dilated cardiomyopathy, showing a hazard ratio of 2.1 with a P value less than 0.001. High-risk genotypes were also identified as an independent predictor, with a hazard ratio of 2.0 and a P value less than 0.001. Patients exhibiting both L. G. E. corridors and high-risk genotypes faced a five-fold higher risk of major ventricular arrhythmic events compared to those without either factor, achieving a hazard ratio of 5.0 with a P value less than 0.001. This combined risk stratification approach identified 79 percent of major ventricular arrhythmic events within 28 percent of the cohort at three years.
Article 5: An Updated Evidence Assessment of the Genetic Causes of Dilated Cardiomyopathy.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/42708185
Summary: The Clinical Genome Resource Dilated Cardiomyopathy gene curation expert panel reconvened to conduct an updated evidence assessment of genes associated with dilated cardiomyopathy. This reassessment applied the Clinical Genome Resource semiquantitative clinical validity classification framework, with specific parameters for dilated cardiomyopathy, to classify the implicated disease genes. The work provides an updated classification of the diverse genetic architecture of dilated cardiomyopathy. This refined classification aims to improve the clinical relevance and understanding of these genetic causes.
đ Transcript
Today’s date is September 09, 2026. Welcome to Cardiology Today. Here are the latest research findings.
Article number one. Tozorakimab to Prevent COPD Exacerbations. Tozorakimab is a monoclonal antibody that inhibits interleukin-33 activity, a key mechanism implicated in the pathogenesis of chronic obstructive pulmonary disease. This therapeutic approach targets the dysregulated signaling in patients who continue to experience exacerbations despite standard-of-care inhaled maintenance therapy. The OBERON and TITANIA phase three trials investigated tozorakimab for preventing exacerbations in adults with chronic obstructive pulmonary disease who were current or former smokers and had a history of exacerbations. The clinical focus is on providing a new preventative option for this high-risk patient population.
Article number two. Impaired Glycolysis Leads to Defective Efferocytosis and Impaired Plaque Resolution in Tet2 Clonal Hematopoiesis. The study found that TET2 (tet methylcytosine dioxygenase two) clonal hematopoiesis impairs glycolysis in macrophages. This impaired glycolysis leads to defective efferocytosis, consequently resulting in impaired plaque resolution within atherosclerotic plaques. The data showed that TET2 clonal hematopoiesis promotes atherosclerosis progression. These mechanisms were observed to impair plaque remodeling and regression even under conditions of low-density lipoprotein lowering.
Article number three. Macrotroponin Complexes and Risk of Cardiovascular Events. The study found that macrotroponin complexes were present in a general population cohort of 19499 participants, with macrotroponin I found in 0.8 percent and macrotroponin T in 0.2 percent. Results showed that macrotroponin I was associated with a lower risk of all-cause mortality, with a hazard ratio of 0.61 and a 95 percent confidence interval of 0.46 to 0.80. This association for macrotroponin I also extended to cardiovascular mortality, showing a hazard ratio of 0.52 with a 95 percent confidence interval of 0.30 to 0.90, even after adjusting for cardiac troponin levels and confounders. No significant association was observed between macrotroponin T and clinical outcomes.
Article number four. Arrhythmic Risk Stratification According to LGE Corridors and Genetics in Nonischemic Dilated Cardiomyopathy. The study found that late gadolinium enhancement (L. G. E.) corridors, assessed through cardiac magnetic resonance imaging, were an independent predictor of major ventricular arrhythmic events in nonischemic dilated cardiomyopathy, showing a hazard ratio of 2.1 with a P value less than 0.001. High-risk genotypes were also identified as an independent predictor, with a hazard ratio of 2.0 and a P value less than 0.001. Patients exhibiting both L. G. E. corridors and high-risk genotypes faced a five-fold higher risk of major ventricular arrhythmic events compared to those without either factor, achieving a hazard ratio of 5.0 with a P value less than 0.001. This combined risk stratification approach identified 79 percent of major ventricular arrhythmic events within 28 percent of the cohort at three years.
Article number five. An Updated Evidence Assessment of the Genetic Causes of Dilated Cardiomyopathy. The Clinical Genome Resource Dilated Cardiomyopathy gene curation expert panel reconvened to conduct an updated evidence assessment of genes associated with dilated cardiomyopathy. This reassessment applied the Clinical Genome Resource semiquantitative clinical validity classification framework, with specific parameters for dilated cardiomyopathy, to classify the implicated disease genes. The work provides an updated classification of the diverse genetic architecture of dilated cardiomyopathy. This refined classification aims to improve the clinical relevance and understanding of these genetic causes.
Thank you for listening. Don’t forget to subscribe.
đ Keywords
Dilated cardiomyopathy, high-risk genotypes, Clinical Genome Resource, plaque resolution, efferocytosis, general population, glycolysis, interleukin-33, Macrotroponin, gene curation, Tozorakimab, cardiovascular events, genetic causes, clinical validity, chronic obstructive pulmonary disease, monoclonal antibody, TET2 clonal hematopoiesis, cardiac troponin I, mortality risk, risk stratification, cardiac troponin T, macrophages, LGE corridors, COPD exacerbations, Late gadolinium enhancement, genetic architecture, nonischemic dilated cardiomyopathy, ventricular arrhythmias, atherosclerosis.
âšī¸ About
Concise summaries of cardiovascular research for professionals.
Subscribe âĸ Share âĸ Follow